<DOC>
	<DOCNO>NCT00564057</DOCNO>
	<brief_summary>Human immunodeficiency virus infection highly active antiretroviral therapy ( HAART ) associate increase risk cardiovascular disease : wide range alteration lipid glucose metabolism increasingly recognize HIV patient treat HAART . Few data available effect antihypertensive treatment cardiac morpho-functional characteristic metabolic parameter HIV patient . Aim study ass effect chronic therapy angiotensin receptor blocker ( candesartan ) calcium channel blocker ( lercanidipine ) metabolic profile cardiac remodelling HIV hypertensive patient .</brief_summary>
	<brief_title>Effects Antihypertensive Treatment HIV Infected Patients : Candesartan Versus Lercanidipine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>HIV infection office blood pressure &gt; 140/90 mmHg antihypertensive treatment good quality echocardiogram cardiovascular disease hypothyroidism diabetes secondary hypertension hepatic renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>blood pressure</keyword>
	<keyword>left ventricle</keyword>
	<keyword>metabolic profile</keyword>
	<keyword>treatment experience</keyword>
</DOC>